International Diabetes Federation.
Diabetes Atlas. International Diabetes
Wild, S, Roglic, G, Green, A, Sicree, R, King, H. Global prevalence of diabetes: estimates for the
year 2000 and projections for 2030. Diabetes
2004; 27: 1047–53.
Amos, A, McCarty, D, Zimmet, P. The rising global burden of diabetes and its
complications: estimates and projections to the year
2010. Diabet Med
Dixon, L, Weiden, P, Delahanty, J. Prevalence and correlates of diabetes in national
schizophrenia samples. Schizophr Bull
2000; 2: 903–12.
Hägg, S, Joelsson, L, Mjörndal, T, Spigset, O, Oja, G, Dahlqvist, R. Prevalence of diabetes and impaired glucose
tolerance in patients treated with clozapine compared with patients
treated with conventional depot neuroleptic medications.
J Clin Psychiatry
1998; 59: 294–9.
Mukherjee, S, Decina, P, Bocola, V, Saraceni, F, Scapicchio, PL. Diabetes mellitus in schizophrenic
patients. Compr Psychiatry
Regenold, WT, Thapar, RK, Marano, C, Gavirneni, S, Kondapavuluru, PV. Increased prevalence of type 2 diabetes mellitus
among psychiatric inpatients with bipolar I affective and schizoaffective
disorders independent of psychotropic drug use. J
Sernyak, MJ, Leslie, DL, Alarcon, RD, Losonczy, MF, Rosenheck, R. Association of diabetes mellitus with use of first
generation neuroleptics in the treatment of
schizophrenia. Am J Psychiatry
2002; 159: 561–6.
Holt, RIG, Peveler, RC, Byrne, CD. Schizophrenia, the metabolic syndrome and
diabetes. Diabet Med
2004; 21: 515–23.
Ananth, J, Venkatesh, R, Burgoyne, K, Gunatilake, S. Atypical antipsychotic drug use and
diabetes. Psychother Psychosom
2002; 71: 244–54.
Erle, G, Basso, M, Federspil, G, Sicolo, N, Scandellari, C. Effect of chlorpromazine on blood glucose and plasma
insulin in man. Eur J Clin Pharmacol
1977; 11: 15–8.
Henderson, D. Atypical antipsychotic-induced diabetes mellitus.
How strong is the evidence?
British Medical Association & Royal
Pharmaceutical Society of Great Britain. British
National Formulary. BMJ Books &
Stroup, DF, Berlin, JA, Morton, SC, Olkin, I, Williamson, GD, Rennie, D, Moher, D, Becker, BJ, Sipe, TA, Thacker, SB. Meta-analysis of observational studies in
epidemiology: a proposal for reporting. Meta-analysis Of Observational
Studies in Epidemiology (MOOSE) group.
2000; 283: 2008–12.
American Diabetes Association.
Report of the expert committee on the diagnosis and
classification of diabetes mellitus. Diabetes
1997; 20: 1183–7.
World Health Organization.
Definition, Diagnosis and Classification of Diabetes Mellitus and
its Complications: Part 1. Diagnosis and Classification of Diabetes
Mellitus. World Health
Juni, P, Altman, DG, Egger, M. Systematic Reviews in Health Care. Assessing the Quality of
Randomized Controlled Trials. BMJ
Woodward, M. Epidemiology: Study Design and Data Analysis.
(2nd edn) (ed. Raton, B.). Chapman and Hall/CRC Press,
Lambert, BL, Chou, CH, Chang, KY, Tafesse, E, Carson, W. Antipsychotic exposure and type 2 diabetes among
patients with schizophrenia: a matched case-control study of California
Medicaid claims. Pharmacoepidemiol Drug
2005; 14: 417–25.
Lambert, BL, Cunningham, FE, Miller, DR, Dalack, GW, Hur, K. Diabetes risk associated with use of olanzapine,
quetiapine, and risperidone in veterans health administration patients
with schizophrenia. Am J Epidemiol
2006; 164: 672–81.
Leslie, DL, Rosenheck, RA. Incidence of newly diagnosed diabetes attributable
to first generation antipsychotic medications. Am
2004; 161: 1709–11.
Lund, BC, Perry, PJ, Brooks, JM, Arndt, S. Clozpine use in patients with schizophrenia and the
risk of diabetes, hyperlipidemia, and hypertension. A claims-based
approach. Arch Gen Psychiatry
2001; 58: 1172–6.
Ollendorf, DA, Joyce, AT, Rucker, M. Rate of new-onset diabetes among patients treated
with first generation or conventional antipsychotic medications for
2004; 6: 5.
Zhao, Z, Tunis, SL, Loosbrock, DL. Risk of diabetes for individuals with schizophrenia
treated with antipsychotics. J Appl Res
2003; 3: 287–95.
Koro, CE, Fedder, DO, L'Italien, GJ, Weiss, SS, Magder, LS, Kreyenbuhl, J, Revicki, DA, Buchanan, RW. Assessment of independent effect of olanzapine and
risperidone on risk of diabetes among patients with schizophrenia:
population based nested case-control study.
2002; 325: 243–5.
Spitzer, RL, Williams, JBW, Gibbon, M, First, MB. Structured Clinical Interview for DSM-III-R
(SCID). New York State Psychiatric Research
Chae, B-J, Kang, B-J. The effect of clozapine on blood glucose
metabolism. Hum Psychopharmacol
2001; 16: 265–71.
Miller, MJ, Molla, PM. Prevalence of diabetes mellitus in patients
receiving depot neuroleptics or clozapine. Arch
2005; 19: 30–4.
Cohen, D, Dekker, JJ, Peen, J, Gispen-de Wied, CC. Prevalence of diabetes mellitus in chronic
schizophrenic inpatients in relation to long-term antipsychotic
treatment. Eur Neuropsychopharmacol
2006; 16: 187–94.
World Health Organization. The
ICD-10 Classification of Diseases and Related Health Problems. Tenth
Revision. World Health
Kurt, E, Oral, ET, Verimli, A. Comparison of the effects of classical and novel
antipsychotic drugs on the insulin and glucose metabolisms of patients
with schizophrenia or other psychotic disorders
[Turkish]. Klinik Psikofarmakoloji Buelteni
Lindenmayer, JP, Czobor, P, Volavka, J, Citrome, L, Sheitman, B, McEvoy, JP, Cooper, TB, Chakos, M, Lieberman, JA. Changes in glucose and cholesterol levels in
patients with schizophrenia treated with second generation or first
generation antipsychotics. Am J
2003; 160: 290–6.
Holt, RIG, Peveler, RC. Antipsychotic drugs and diabetes - an application of
the Austin Bradford Hill criteria.
2006; 49: 1467–76.
Etminan, M, Streiner, DL, Rochon, PA. Exploring the association between atypical
neuroleptic agents and diabetes mellitus in older adults.
2003; 23: 1411–5.
Citrome, L, Jaffe, A, Levine, J, Allingham, B, Robinson, J. Relationship between antipsychotic medication
treatment and new cases of diabetes among psychiatric
inpatients. Psychiatr Serv
2004; 55: 1006–13.
Gianfrancesco, FD, Grogg, AL, Mahmoud, RA, Wang, RH, Nasrallah, HA. Differential effects of risperidone, olanzapine,
clozapine, and conventional antipsychotics on type 2 diabetes: findings
from a large health plan database. J Clin
2002; 63: 920–30.
Gianfresco, F, White, R, Wang, R, Nasrallah, HA. Antipsychotic-induced type 2 diabetes: evidence from
a large health plan database. J Clin
2003; 23: 328–35.
Gupta, S, Steinmeyer, C, Frank, B, Madhusoodanan, S, Lockwood, K, Lentz, B, Keller, P. Hyperglycemia and hypertriglyceridemia in real world
patients on antipsychotic therapy. Am J
2003; 10: 348–55.
Sacchetti, E, Turrina, C, Parrinello, G, Brignoli, O, Stefanini, G, Mazzaglia, G. Incidence of diabetes in a general practice
population: a database cohort study on the relationship with haloperidol,
olanzapine, risperidone or quetiapine exposure.
Int Clin Psychopharmacol
2005; 20: 33–7.
Spanarello, S, Beoni, AM, Mina, G, Colotto, A. Antipsicotici e implicazioni
metaboliche. Minerva Psychiatr
Brown, RR, Estoup, MW. Comparison of the metabolic effects observed in
patients treated with ziprasidone versus olanzapine.
Int Clin Psychopharmacol
2005; 20: 105–12.
Caro, JJ, Ward, A, Levinton, C, Robinson, K. The risk of diabetes during olanzapine use compared
with risperidone use: a retrospective database analysis.
J Clin Psychiatry
2002; 63: 1135–9.
Melkersson, KI, Dahl, ML. Relationship between levels of insulin or
triglycerides and serum concentrations of the atypical antipsychotics
clozapine and olanzapine in patients on treatment with therapeutic
2003; 170: 157–66.
Meyer, JM. A retrospective comparison of weight, lipid, and
glucose changes between risperidone- and olanzapine-treated inpatients:
metabolic outcomes after 1 year. J Clin
2002; 63: 425–33.
Ananth, J, Parameswaran, S, Gunatilake, S. Side effects of atypical antipsychotic
drugs. Curr Pharm Des
2004; 10: 2219–29.
Mackin, P, Watkinson, HM, Young, AH. Prevalence of obesity, glucose homeostasis disorders
and metabolic syndrome in psychiatric patients taking typical or atypical
antipsychotic drugs: a cross-sectional study.
2005; 48: 215–21.
Jin, H, Meyer, JM, Jeste, DV. Phenomenology of and risk factors for new-onset
diabetes mellitus and diabetic ketoacidosis associated with atypical
antipsychotics: an analysis of 45 published cases.
Ann Clin Psychiatry
Geddes, J, Freemantle, N, Harrison, P, Bebbington, P. Atypical antipsychotics in the treatment of
schizophrenia: systematic review and meta-regression
2000; 321: 1371–6.
Subramaniam, M, Chong, SA, Pek, E. Diabetes mellitus and impaired glucose tolerance in
patients with schizophrenia. Can J
2003; 48: 345–7.
Hill, A. The environment and disease: association or
causation. Proc R Soc Med